Download PDF
Exp Clin Endocrinol Diabetes 2020; 128(05): 319-324
DOI: 10.1055/a-0647-6860
Article
© Georg Thieme Verlag KG Stuttgart · New York

Elevation in Circulating Soluble CD40 Ligand Concentrations in Type 2 Diabetic Retinopathy and Association with its Severity

Laila Ben Lamine
1   Laboratory of Human Genome and Multifactorial Diseases (LR12ES07), Faculty of Pharmacy of Monastir, University of Monastir, Tunisia
,
Amira Turki
1   Laboratory of Human Genome and Multifactorial Diseases (LR12ES07), Faculty of Pharmacy of Monastir, University of Monastir, Tunisia
2   Faculty of Applied Medical Sciences, Northern Borders University, Arar, Saudi Arabi
,
Ghada Al-Khateeb
3   Department of Ophthalmology, Goethe-University, Frankfurt am Main, Germany
,
Nejla Sellami
1   Laboratory of Human Genome and Multifactorial Diseases (LR12ES07), Faculty of Pharmacy of Monastir, University of Monastir, Tunisia
4   Faculty of Science of Bizerte, University of Carthage, Tunisia
,
Hagger B. Amor
5   Department of Ophthalmology, Fattouma Bourguiba University Hospital, Faculty of Medicine, University of Monastir, Monastir, Tunisia
,
Sameh Sarray
6   College of Medicine and Medical Sciences, Arabian Gulf University, Manama, Bahrain
7   Faculty of Sciences, El Manar University, 2092 Manar II, Tunisia
,
Mohamed Jailani
6   College of Medicine and Medical Sciences, Arabian Gulf University, Manama, Bahrain
,
Mohamed Ghorbel
8   Department of Ophthalmology, CHU Farhat Hached, Sousse, Tunisia
,
Touhami Mahjoub
1   Laboratory of Human Genome and Multifactorial Diseases (LR12ES07), Faculty of Pharmacy of Monastir, University of Monastir, Tunisia
,
Wassim Y. Almawi
7   Faculty of Sciences, El Manar University, 2092 Manar II, Tunisia
9   School of Pharmacy, Lebanese American University, Byblos, Lebanon
› Author Affiliations
Further Information

Publication History

received 21 April 2018
revised 19 June 2018

accepted 22 June 2018

Publication Date:
27 August 2018 (online)

Also available at
    Permissions and Reprints

Abstract

Background To investigate the relationship between changes in circulating soluble CD40 ligand (sCD40L) levels and the presence and severity of type 2 diabetic retinopathy (DR).

Subjects and methods sCD40L plasma concentrations were measured in 205 type 2 diabetes (T2DM) patients without DR (DWR; n=50) and with DR (n=155), the latter subdivided into non-proliferative diabetic retinopathy [NPDR; n=98 (63.2%)], or proliferative retinopathy [PDR; n=57 (36.8%)] patients.

Results Receiver operating characteristic analysis provided good discriminatory power for sCD40L as predictor of DR presence, with high sensitivity and specificity. Categorizing DWR and DR patients into sCD40L quartiles, based on sCD40L concentrations in T2DM without DR, demonstrated statistically significant gradual increase in DR risk with increasing sCD40L levels. sCD40L levels were significantly higher in DR compared to DWR patients. Plasma sCD40L levels differed significantly according to DR severity, and correlated with diabetes duration, dyslipedimea, nephropathy, and presence of DR, but not with gender, age, SBP, DBP, FPG, HbA1c, T2DM medications. Linear regression analysis confirmed the association of increased sCD40L levels with DR, independent of others parameters; mean plasma sCD40L levels differing significantly according to DR severity.

Conclusion Plasma sCD40L levels were positively associated with DR. The significant finding here is that sCD40L levels can be predictors of DR severity.

Key words

Diabetic retinopathy - obesity - sCD40L - type 2 diabetes
 

  • References

  • 1 Klein BE. Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic Epidemiol 2007; 14: 179-183
    CrossrefPubMedGoogle Scholar
  • 2 Whiting DR, Guariguata L, Weil C. et al. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011; 94: 311-213
    CrossrefPubMedGoogle Scholar
  • 3 Kahloun R, Jelliti B, Zaouali S. et al. Visual impairment in Tunisian diabetic patients. Eye 2014; 28: 986-991
    CrossrefPubMedGoogle Scholar
  • 4 Williams R, Airey M, Baxter H. et al. Epidemiology of diabetic retinopathy and macular oedema: A systematic review. Eye (Lond) 2004; 18: 963-983
    PubMedGoogle Scholar
  • 5 Ezzidi I, Mtiraoui N, Mohamed MB. et al. Endothelial nitric oxide synthase Glu298Asp, 4b/a, and T-786C polymorphisms in type 2 diabetic retinopathy. Clin Endocrinol (Oxf) 2008; 68: 542-546
    CrossrefPubMedGoogle Scholar
  • 6 Meleth AD, Agron E, Chan CC. et al. Serum inflammatory markers in diabetic retinopathy. Invest Ophthalmol Vis Sci 2005; 46: 4295-4301
    CrossrefPubMedGoogle Scholar
  • 7 Tomić M, Ljubić S, Kaštelan S. et al. Inflammation, haemostatic disturbance, and obesity: possible link to pathogenesis of diabetic retinopathy in type 2 diabetes. Mediators Inflamm 2013; 2013: 818671
    PubMedGoogle Scholar
  • 8 Roy S, Kim D, Lim R. Cell-cell communication in diabetic retinopathy. Vision Res 2017; 139: 115-122
    CrossrefPubMedGoogle Scholar
  • 9 Battaglia Parodi M, Iacono P, Cascavilla ML. et al. Sequential anterior ischemic optic neuropathy and central retinal artery and vein occlusion after ranibizumab for diabetic macular edema. Eur J Ophthalmol 2010; 20: 1076-1078
    CrossrefPubMedGoogle Scholar
  • 10 Bae SH, Lee J, Roh KH. et al. Platelet activation in patients with diabetic retinopathy. Korean J Ophthalmol 2003; 17: 140-144
    CrossrefPubMedGoogle Scholar
  • 11 Zhang W, Liu H, Rojas M. et al. Anti-inflammatory therapy for diabetic retinopathy. Immunotherapy 2011; 3: 609-628
    CrossrefPubMedGoogle Scholar
  • 12 Elgueta R, Benson MJ, de Vries VC. et al Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev 2009; 229: 152-172
    CrossrefPubMedGoogle Scholar
  • 13 Zhang B, Wu T, Chen M. et al. The CD40/CD40L system: a new therapeutic target for disease. Immunol Lett 2013; 153: 58-61
    CrossrefPubMedGoogle Scholar
  • 14 Chen J, Li JH, Zhao SJ. et al. Clinical significance of costimulatory molecules CD40/ CD40L and CD134/CD134L in coronary heart disease: A case-control study. Medicine (Baltimore) 2017; 96: e7634
    PubMedGoogle Scholar
  • 15 Zhao W, Zhang F, Li Z. et al. Soluble CD40 ligand is associated with angiographic severity of coronary artery disease in patients with acute coronary syndrome. Chin Med J (Engl) 2014; 127: 2218-2221
    PubMedGoogle Scholar
  • 16 Xie JX, Alderson H, Ritchie J. et al. Circulating CD40 and sCD40L Predict Changes in Renal Function in Subjects with Chronic Kidney Disease. Sci Rep 2017; 7: 7942
    CrossrefPubMedGoogle Scholar
  • 17 Cipollone F, Chiarelli F, Davì G. et al. Enhanced soluble CD40 ligand contributes to endothelial cell dysfunction in vitro and monocyte activation in patients with diabetes mellitus: effect of improved metabolic control. Diabetologia 2005; 48: 1216-1224
    CrossrefPubMedGoogle Scholar
  • 18 Linna H, Suija K, Rajala U. et al. The association between impaired glucose tolerance and soluble CD40 ligand: a 15-year prospective cohort study. Aging Clin Exp Res. 2016; 28: 1243-1249
    CrossrefPubMedGoogle Scholar
  • 19 Metwalley KA, Farghaly HS, El-Saied AR. Assessment of serum levels of soluble CD40L in Egyptian children and adolescents with type 1 diabetes mellitus: Relationship to microalbuminuria and glycemic control. Indian J Endocrinol Metab 2013; 17: 1024-1029
    CrossrefPubMedGoogle Scholar
  • 20 Neubauer H, Setiadi P, Günesdogan B. et al. Influence of glycaemic control on platelet bound CD40-CD40L system, P-selectin and soluble CD40 ligand in type 2 diabetes. Diabet Med 2010; 27: 384-390
    CrossrefPubMedGoogle Scholar
  • 21 Varo N, Vicent D, Libby P. et al. Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones. Circulation 2003; 107: 2664-2673
    CrossrefPubMedGoogle Scholar
  • 22 Lim HS, Blann AD, Lip GY. Soluble CD40 ligand, soluble P-selectin, interleukin-6, and tissue factor in diabetes mellitus: relationships to cardiovascular disease and risk factor intervention. Circulation 2004; 109: 2524-2528
    CrossrefPubMedGoogle Scholar
  • 23 Yngen M, Östenson CG, Hu H. et al. Enhanced P-selectin expression and increased soluble CD40 Ligand in patients with Type 1 diabetes mellitus and microangiopathy: evidence for platelet hyperactivity and chronic inflammation. Diabetologia 2004; 47: 537-540
    CrossrefPubMedGoogle Scholar
  • 24 Lima VC, Cavalieri GC, Lima MC. et al. Risk factors for diabetic retinopathy: a case-control study. Int J Retina Vitreous 2016; 12: 2-21
    PubMedGoogle Scholar
  • 25 Shaheer AK, Tharayil JK, Krishna PW. A Comparative Study of High Sensitivity C-Reactive Protein and Metabolic Variables in Type 2 Diabetes Mellitus with and without Nephropathy. J Clin Diagn Res 2017; 11: BC01-BC04
    PubMedGoogle Scholar
  • 26 Lajer M, Tarnow I, Michelson AD. et al. Soluble CD40 ligand is elevated in type 1 diabetic nephropathy but not predictive of mortality, cardiovascular events or kidney function. Platelets 2010; 21: 525-532
    CrossrefPubMedGoogle Scholar
  • 27 Harding SA, Sommerfield AJ, Sarma J. et al. Increased CD40 ligand and platelet-monocyte aggregates in patients with type 1 diabetes mellitus. Atherosclerosis 2004; 176: 321-325
    CrossrefPubMedGoogle Scholar
  • 28 Novo S, Basili S, Tantillo R. et al. Soluble CD40L and cardiovascular risk in asymptomatic low-grade carotid stenosis. Stroke 2005; 36: 673-675
    CrossrefPubMedGoogle Scholar
  • 29 Denis GV, Sebastiani P, Andrieu G. et al. Relationships Among Obesity, Type 2 diabetes, and plasma cytokines in African American women. Obesity (Silver Spring) 2017; 25: 1916-1920
    CrossrefPubMedGoogle Scholar
  • 30 Unek IT, Bayraktar F, Solmaz D. et al. The levels of soluble CD40 ligand and C-reactive protein in normal weight, overweight and obese people. Clin Med Res 2010; 8: 89-95
    CrossrefPubMedGoogle Scholar
  • 31 Gateva A, Assyov Y, Tsakova A. et al. Soluble CD40L is associated with insulin resistance, but not with glucose tolerance in obese nondiabetic patients. Arch Physiol Biochem 2016; 122: 161-165
    CrossrefPubMedGoogle Scholar
  • 32 Martín-Merino E, Fortuny J, Rivero-Ferrer E. et al. Risk factors for diabetic retinopathy in people with Type 2 diabetes: A case-control study in a UK primary care setting. Prim Care Diabetes 2016; 10: 300-308
    CrossrefPubMedGoogle Scholar
  • 33 Kumar B, Kowluru A, Kowluru RA. Lipotoxicity augments glucotoxicity-induced mitochondrial damage in the development of diabetic retinopathy. Invest Ophthalmol Vis Sci 2015; 56: 2985-2992
    CrossrefPubMedGoogle Scholar
  • 34 Sharma Y, Saxena S, Mishra A. et al. Nutrition for diabetic retinopathy: plummeting the inevitable threat of diabetic vision loss. Eur J Nutr 2017; 56: 2013-2027
    CrossrefPubMedGoogle Scholar
  • 35 Baptista FI, Castilho ÁF, Gaspar JM. et al. Long-term exposure to high glucose increases the content of several exocytotic proteins and of vesicular GABA transporter in cultured retinal neural cells. Neurosci Lett 2015; 602: 56-61
    CrossrefPubMedGoogle Scholar
  • 36 Cundiff DK, Nigg CR. Diet and diabetic retinopathy: insights from the Diabetes Control and Complications Trial (DCCT). Med Gen Med 2005; 7: 3
    PubMedGoogle Scholar
  • 37 Danese S, Katz JA, Saibeni S. et al. Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients. Gut 2003; 52: 1435-1441
    CrossrefPubMedGoogle Scholar